Imbruvica’s New Label Opens Door For Use With Popular Rituxan Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves language about survival benefit in first-line CLL and also for use across lines of therapy with bendamustine/Rituxan, the market-leading combo treatment.